EP2504698B1 - Procédé permettant de prévoir la réponse d'une pathologie tumorale à une mesure thérapeutique - Google Patents

Procédé permettant de prévoir la réponse d'une pathologie tumorale à une mesure thérapeutique Download PDF

Info

Publication number
EP2504698B1
EP2504698B1 EP10787078.4A EP10787078A EP2504698B1 EP 2504698 B1 EP2504698 B1 EP 2504698B1 EP 10787078 A EP10787078 A EP 10787078A EP 2504698 B1 EP2504698 B1 EP 2504698B1
Authority
EP
European Patent Office
Prior art keywords
tumor cells
cells
epithelial
tumor
epithelial tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP10787078.4A
Other languages
German (de)
English (en)
Other versions
EP2504698A1 (fr
Inventor
Ulrich Pachmann
Katharina Pachmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to PL10787078T priority Critical patent/PL2504698T3/pl
Priority to SI201031705T priority patent/SI2504698T1/sl
Publication of EP2504698A1 publication Critical patent/EP2504698A1/fr
Application granted granted Critical
Publication of EP2504698B1 publication Critical patent/EP2504698B1/fr
Priority to HRP20180906TT priority patent/HRP20180906T1/hr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Definitions

  • the invention relates to a method for predicting the response of a tumor of a patient caused by a solid epithelial tumor tumor disease to a therapeutic measure.
  • a solid tumor is understood to mean a tumor whose cells grow in the cell network and thereby form a firm, locally circumscribed tissue. It is known that cells detach from such a tumor and be distributed through the blood or lymph in the body.
  • chemosensitivity chemosensitivity to cancer cells.
  • chemosensitivity to cytostatic agents from the group of alkylating agents that act via a genetic modification of the tumor cells may be diminished by the activation of DNA repair enzymes in tumor cells.
  • a reduced transport of cytostatics into the cell interior, the inactivation of cytostatic drugs or even the lack of expression of effect-promoting receptors can lead to a reduction in the chemosensitivity of the tumor cells.
  • a reduced chemosensitivity of the tumor cells can cause a lack of therapeutic success.
  • each patient responds individually to a particular chemotherapeutic agent because of its genetic background and the development of subclones within a tumor.
  • cells from tissue pieces of the tumor are initially obtained before treatment of the tumor by digesting the tumor tissue of the tissue pieces with proteolytically active enzymes. Subsequently, the chemosensitivity of the cells obtained from the tumor tissue and cultured for a long time compared with various chemotherapeutic agents in vitro is determined. For this purpose, it is checked whether the cultured cells proliferate in the presence of a particular chemotherapeutic agent or whether they die in its presence.
  • the method is intended to largely prevent a patient being treated with a chemotherapy drug that is ineffective or ineffective for him.
  • CETCs blood epithelial Tumor cells
  • the drug response indicators may be cellular components related to the mechanism of action of the chemotherapeutic agent.
  • these may be the DNA repair protein ERCC1, beta-tubulin III, thymidylate synthase, topoisomerase II, topoisomerase I or ribonuclease reductase.
  • cell lines are used. The cells are seeded and kept for 24 hours at 37 ° C in 5% CO 2 atmosphere. Thereafter, the cells are exposed to the respective drug. In the case of tamoxifen, the cells are cultured for 72 hours to confluency. Subsequently, medium containing 0.5% FCS (fetal calf serum) is added to maximize estrogen receptor expression. Controls contain a suitable medium and are treated the same as the treated cells. 72 hours after treatment, the number of living cells for each drug concentration is determined by means of a tetrazolium salt. As a result, the percentage inhibition of growth compared to the drug concentration is obtained.
  • FCS fetal calf serum
  • the DE 198 33 738 A1 discloses a method for isolating cancer cells from bodily fluids, in which the cancer cells are retained by a sieve.
  • the isolated cells can be cultured in vitro with the addition of cytostatics, so that different forms of therapy can be tested in vitro and individually optimized for each patient.
  • the WO 03/065042 A1 relates to a method of assessing the presence of a malignancy in which a sample having a mixed cell population containing hematopoietic and non-hematopoietic malignant cells is contacted with a detectable ligand specifically reactive with the malignant cells and at least one reagent which also specifically labels the malignant cells becomes. Subsequently, the number of labeled cells is analyzed to determine the presence and number of malignant cells. Furthermore, changes in at least one tumor diathesis-associated Molecule determined. The labeled malignant cells may be contacted with a chemotherapeutic agent to determine their sensitivity.
  • the object of the present invention is to provide an alternative method which can be carried out quickly and which, before carrying out a therapeutic measure against a tumor disease proceeding from a solid epithelial tumor, makes it possible to predict whether the tumor is sensitive to the therapeutic measure.
  • a method for predicting the response of a tumor tumor of a patient to a therapeutic action caused by a solid epithelial tumor wherein epithelial tumor cells from a body fluid of the patient are each received in a cell culture medium.
  • the epithelial tumor cells contained in the body fluid are cells detached from the solid tumor.
  • the cell culture medium is a medium that preserves the viability of the tumor cells in cell culture. Numerous such media, such as. Ham's F12 or RPMI are known.
  • the cell culture medium contains no added growth factor or serum, such as fetal calf serum. This causes a selection of the epithelial tumor cells compared to other cells possibly contained, because the tumor cells, in contrast to the other cells do not need externally added growth factors for survival or proliferation.
  • the tumor cells from a sample of the cell culture medium containing the tumor cells are subjected to the therapeutic action while the tumor cells from a control sample of the cell culture medium containing the tumor cells remain untreated. Subsequently, the proportion of dying and dead epithelial tumor cells in the total number of epithelial tumor cells and of the one by the therapeutisehe is determined for the sample and the control sample Measure conditional mortality rate of epithelial tumor cells determined as a measure of response.
  • the proportion of dying and dead epithelial tumor cells can also be determined indirectly by determining the proportion of living and non-dying epithelial tumor cells in the total number of epithelial tumor cells and subtracting them from the total number (100% or 1).
  • the proportion of dying and dead or living and non-dying epithelial tumor cells can be determined by means of cytometric or image-analytical methods.
  • the rate of death of the epithelial tumor cells due to the therapeutic action is determined by subtracting the proportion of dying and dead epithelial tumor cells in the control sample from the proportion of dying and dead epithelial tumor cells in the sample.
  • the rate of death may be determined as a function of time and / or as a function of the concentration of a chemotherapeutic agent or the intensity of a therapeutic measure, for example an irradiation.
  • a great advantage with regard to the burden on the patient and a quick execution of the method is that no material to be taken from the solid epithelial tumor is required for carrying out the method.
  • the method according to the invention it is not necessary to cultivate the epithelial tumor cells before they are subjected to the therapeutic measure.
  • the tumor cells can be exposed to the therapeutic action immediately after ingestion in the cell culture medium.
  • Between the therapeutic action and the determination of the proportion of dying and dead epithelial tumor cells in the total number of epithelial tumor cells may be a time of one hour to several days, in particular of 2 hours, 3 hours, 1 day, 2 days or 3 days.
  • the tumor cells are kept under usual cell culture conditions, which allow a survival of the tumor cells in the cell culture medium without therapeutic measures.
  • cell culture conditions include a CO 2 content of the atmosphere of 5% -10% and a temperature of 37 ° C.
  • the cell culture medium contains no added growth factor and no added serum containing growth factors.
  • the inventors have recognized that the response of cells of a solid epithelial tumor present in a body fluid of a patient to a therapeutic action is useful in predicting the response of a tumor disease caused by that tumor to the therapeutic action. This is surprising because it has previously been thought that most of the tumor cells present in the body fluid are present in the body fluid because they have lost their ability to grow in association with other cells of the tumor. It has therefore been assumed that they are not representative of a solid tumor. However, the inventors have recognized that the existing in a body fluid epithelial tumor cells can change so that they can settle again and grow in the cell composite. Thus, they play a crucial role in the often life-threatening metastasis.
  • the tumor disease may also be a minimal residual disease or a recurrence of the tumor disease in the form of metastases after complete removal of a primary tumor.
  • epithelial tumor cells can often be present even years after the removal of a solid epithelial primary tumor. In such a case, a tissue extraction from the solid tumor, as in Kunststoffiani et al. described is not possible.
  • the method according to the invention it is possible to check, before starting a therapy without removing a tissue sample from the solid tumor of a patient, whether a contemplated therapeutic measure is suitable for the therapy of the tumor disease. It allows for individualized patient-specific therapy by means of the therapeutic measure to which the respective patient is most responsive. At the same time, it can be avoided by the method according to the invention that the patient is treated with an ineffective or poorly effective side effect rich expensive therapy for him. Apart from the individual advantages for the individual patient, costs in the healthcare sector can be saved by means of the method according to the invention.
  • the method according to the invention does not require epithelial tumor cell-specific enrichment processes, for example by means of antibody-coated magnetic particles. As a result, a falsification of the determined rate of death is excluded by different or incomplete enrichment for different cells.
  • the method according to the invention does not come without isolation of the cells possibly changing the properties of the tumor cells from the tumor tissue by means of enzymatic digestion and without a chemosensitivity tests hitherto usual long-term cultivation of the tumor cells. In long-term cultivation, the properties, such as the sensitivity of the tumor cells to the therapeutic measure, may change. The isolation of the cells and the long-term cultivation may therefore lead to a falsification of the results.
  • the sensitivity of the tumor to the therapeutic action can be determined specifically and selectively to the epithelial tumor cells obtained from the body fluid.
  • the method according to the invention is thus much faster to perform and leads to a result faster than that, for example, from Mediani et al. known method. It is not necessary to remove the tissue of the solid epithelial tumor from the patient and to cultivate the cells obtained from it before they are subjected to the therapeutic measure. After the cells have been subjected to the therapeutic measure, no growth of the cells is required because in the method according to the invention no growth inhibition must be determined to assess the efficiency of the therapeutic measure.
  • the body fluid may be blood, ascites fluid, lymph, pleural exudate, cerebrospinal fluid or urine.
  • the epithelial tumor cells may be, in particular, circulating epithelial tumor cells (CETCs) occurring in the blood.
  • CETCs circulating epithelial tumor cells
  • the tumor cells Prior to incorporation into the culture medium, the tumor cells alone, taking advantage of their relative to the surrounding body fluid higher specific gravity, in particular by settling or centrifuging. If the body fluid is blood, the red blood cells contained therein may be lysed prior to accumulating the tumor cells. This facilitates later optical, in particular image-analytical, identification of the epithelial tumor cells.
  • the epithelial tumor cells can be brought into contact with a substance which specifically labels the tumor cells, in particular an antibody specific for epithelial cells.
  • the antibody may be, for example, an antibody recognizing the human epithelial antigen, for example the monoclonal antibody HEA-125.
  • the human epithelial antigen also referred to as HEA or CD326, does not exist on blood cells. Since epithelial cells usually do not occur in the body fluid, an antibody which specifically labels epithelial cells, in particular staining antibodies, is sufficient to identify them as epithelial tumor cells.
  • the specific tumor cell-labeling substance is a substance that does not or at least not significantly affect the viability of the epithelial tumor cells.
  • the epithelial tumor cells To identify the dying and dead epithelial tumor cells or the living and non-dying tumor cells, the epithelial tumor cells, a first indicator indicating dying off and / or dead cells, in particular propidium iodide, or a second indicator indicating a specific living cell can be added.
  • a first indicator indicating dying off and / or dead cells in particular propidium iodide
  • a second indicator indicating a specific living cell can be added.
  • propidium iodide the living cells remain unstained because of their intact cell membrane, while the dead and dying cells are stained by the propidium iodide entering the cells.
  • the therapeutic measure may include exposure to radiation or heat, or contacting with a cytostatic, especially 5-fluorouracil, or other anti-tumor therapeutic.
  • the solid epithelial tumor can be a mammary carcinoma or a bronchial carcinoma.
  • Fig. 1 shows the rate of death of cells carrying the human epithelial antigen (HEA) after incubation with 5-fluorouracil and staining with propidium iodide depending on the concentration of 5-fluorouracil used and the incubation time.
  • HAA human epithelial antigen
  • 3 ml of blood mixed with EDTA as anticoagulant are mixed with 30 ml of red blood cell ammonium chloride lysing reagent (Qiagen, 40724 Hilden, Germany) and incubated at 8 to 12 ° C. for 10 minutes.
  • the leukocytes and the epithelial tumor cells are sedimented by centrifugation for 7 minutes at 700 xg. After decanting the supernatant containing the lysed red blood cells, the pellet is resuspended in 50 ml of phosphate buffered saline (PBS) and centrifuged again at 700 xg for 7 minutes.
  • PBS phosphate buffered saline
  • the cell suspension contained in each well is analyzed cytometrically.
  • the proportion of dead cells determined for the control sample is subtracted from the proportion of dead cells determined for each of the samples, thereby determining the time and concentration-dependent mortality rate of the tumor cells attributable to the therapeutic agent.
  • Fig. 1 shows typical curves for different concentrations of the cytostatic 5-fluorouracil after different incubation times.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Physiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Electrotherapy Devices (AREA)

Claims (11)

  1. Procédé de prédiction de la réponse d'une maladie tumorale provoquée par une tumeur épithéliale solide d'un patient à une mesure thérapeutique, dans lequel des cellules tumorales épithéliales provenant d'un fluide corporel du patient sont à chaque fois incorporées dans un milieu de culture cellulaire, dans lequel les cellules tumorales provenant d'un échantillon du milieu de culture cellulaire contenant les cellules tumorales sont exposées à la mesure thérapeutique tandis que les cellules tumorales provenant d'un échantillon témoin du milieu de culture cellulaire contenant les cellules tumorales restent non traitées, dans lequel la proportion de cellules tumorales épithéliales nécrosantes et mortes sur le nombre total des cellules tumorales épithéliales est ensuite à chaque fois déterminée pour l'échantillon et l'échantillon témoin et un taux de nécrose des cellules tumorales épithéliales conditionné par la mesure thérapeutique est déterminé à partir de celle-ci en tant que mesure pour la réponse, dans lequel le milieu de culture cellulaire ne contient aucun facteur de croissance ajouté et aucun sérum ajouté.
  2. Procédé selon la revendication 1, dans lequel une durée de 1 heure à 3 jours, notamment de 2 heures à un jour, se situe entre la mesure thérapeutique et la détermination de la proportion de cellules tumorales épithéliales nécrosantes et mortes sur le nombre total des cellules tumorales épithéliales.
  3. Procédé selon la revendication 2, dans lequel les cellules tumorales sont maintenues pendant la durée dans des conditions de culture cellulaire qui permettent sans mesure thérapeutique une survie des cellules tumorales dans le milieu de culture cellulaire.
  4. Procédé selon une des revendications précédentes, dans lequel le fluide corporel est du sang, du liquide ascitique, de la lymphe, de l'exsudat pleural, du liquide céphalorachidien ou de l'urine.
  5. Procédé selon une des revendications précédentes, dans lequel les cellules tumorales épithéliales sont des cellules tumorales épithéliales circulantes (CETC).
  6. Procédé selon une des revendications précédentes, dans lequel les cellules tumorales sont enrichies avant l'incorporation dans le milieu de culture en exploitant leur poids spécifique supérieur par rapport au fluide corporel les entourant, notamment par précipitation ou centrifugation.
  7. Procédé selon la revendication 6, dans lequel le fluide corporel est du sang et les globules rouges contenus dans celui-ci sont lysés avant l'enrichissement des cellules tumorales.
  8. Procédé selon une des revendications précédentes, dans lequel les cellules tumorales épithéliales sont amenées en contact avec une substance marquant spécifiquement les cellules tumorales, notamment un anticorps spécifique pour des cellules épithéliales, pour la différenciation d'autres cellules présentes dans le fluide corporel.
  9. Procédé selon une des revendications précédentes, dans lequel un premier indicateur indiquant spécifiquement des cellules nécrosantes et/ou mortes, notamment de l'iodure de propidium, ou un second indicateur indiquant spécifiquement des cellules vivantes est ajouté aux cellules tumorales épithéliales.
  10. Procédé selon une des revendications précédentes, dans lequel la mesure thérapeutique comprend une exposition à un rayonnement ou de la chaleur ou une mise en contact avec un agent cytostatique, notamment du 5-fluorouracile, ou un autre agent thérapeutique dirigé contre la tumeur.
  11. Procédé selon une des revendications précédentes, dans lequel la tumeur est un carcinome mammaire ou un carcinome bronchique.
EP10787078.4A 2009-11-25 2010-11-25 Procédé permettant de prévoir la réponse d'une pathologie tumorale à une mesure thérapeutique Active EP2504698B1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
PL10787078T PL2504698T3 (pl) 2009-11-25 2010-11-25 Sposób przewidywania odpowiedzi choroby nowotworowej na środek terapeutyczny
SI201031705T SI2504698T1 (sl) 2009-11-25 2010-11-25 Postopek za napovedovanje odziva tumorskega obolenja na terapevtski ukrep
HRP20180906TT HRP20180906T1 (hr) 2009-11-25 2018-06-11 Postupak predviđanja odgovora tumorske bolesti na terapijske mjere

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE200910047146 DE102009047146B4 (de) 2009-11-25 2009-11-25 Verfahren zum Vorhersagen des Ansprechens einer Tumorerkrankung auf eine therapeutische Maßnahme
PCT/EP2010/068235 WO2011064308A1 (fr) 2009-11-25 2010-11-25 Procédé permettant de prévoir la réponse d'une pathologie tumorale à une mesure thérapeutique

Publications (2)

Publication Number Publication Date
EP2504698A1 EP2504698A1 (fr) 2012-10-03
EP2504698B1 true EP2504698B1 (fr) 2018-03-14

Family

ID=43413696

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10787078.4A Active EP2504698B1 (fr) 2009-11-25 2010-11-25 Procédé permettant de prévoir la réponse d'une pathologie tumorale à une mesure thérapeutique

Country Status (13)

Country Link
EP (1) EP2504698B1 (fr)
JP (1) JP5926187B2 (fr)
CA (1) CA2781727C (fr)
DE (1) DE102009047146B4 (fr)
DK (1) DK2504698T3 (fr)
ES (1) ES2673514T3 (fr)
HR (1) HRP20180906T1 (fr)
HU (1) HUE037770T2 (fr)
PL (1) PL2504698T3 (fr)
PT (1) PT2504698T (fr)
SI (1) SI2504698T1 (fr)
TR (1) TR201808349T4 (fr)
WO (1) WO2011064308A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102012213838A1 (de) * 2012-08-03 2014-02-06 Katharina Pachmann Verfahren zur Kultivierung einer Subpopulation zirkulierender epithelialer Tumorzellen aus einer Körperflüssigkeit
DE102013010528B3 (de) * 2013-06-25 2014-02-20 FLACOD GmbH Verfahren zur Erstellung einer Datenbank für die Vorabschätzung der Wirksamkeit von Wirkstoffen in der Tumortherapie
GB201507894D0 (en) 2015-05-08 2015-06-24 Imagen Biotech Ltd Personalised media

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19833738A1 (de) 1998-07-27 2000-02-03 Michael Giesing Verfahren zur Isolierung von Krebszellen aus zellhaltigen Körperflüssigkeiten sowie Sets zur Durchführung dieses Verfahrens
AU2002306561A2 (en) 2001-02-16 2003-09-02 Immunivest Corporation Methods and reagents for the rapid and efficient isolation of circulating cancer cells
KR20080066663A (ko) 2005-09-21 2008-07-16 씨씨씨 디아그노스틱스 엘엘씨 맞춤화된 항암 화학요법（ｐａｃ）을 위한 종합적인 진단테스트 방법

Also Published As

Publication number Publication date
EP2504698A1 (fr) 2012-10-03
CA2781727A1 (fr) 2011-06-03
SI2504698T1 (sl) 2018-09-28
HUE037770T2 (hu) 2018-09-28
PL2504698T3 (pl) 2018-10-31
DK2504698T3 (en) 2018-06-18
TR201808349T4 (tr) 2018-07-23
CA2781727C (fr) 2018-06-05
PT2504698T (pt) 2018-06-20
DE102009047146B4 (de) 2012-07-19
JP2013511968A (ja) 2013-04-11
JP5926187B2 (ja) 2016-05-25
ES2673514T3 (es) 2018-06-22
DE102009047146A1 (de) 2011-06-01
WO2011064308A1 (fr) 2011-06-03
HRP20180906T1 (hr) 2018-08-24

Similar Documents

Publication Publication Date Title
EP1262776B1 (fr) Procédé pour la détermination quantitative de cellules tumorales épithéliales vivantes dans un fluide corporel
US20050202410A1 (en) Precise efficacy assay methods for active agents inlcluding chemotherapeutic agents
US9012215B2 (en) Methods for identifying leukemia stem cells and distinguishing them from normal hematopietic stem cells in patients with acute myeloid leukemia: uses in diagnosis, treatment, and research
US20070059821A1 (en) Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays
US20190128870A1 (en) Diagnostic Methods For Patient Specific Therapeutic Decision Making In Cancer Care
EP2880152B1 (fr) Procédé de culture d'une sous-population de cellules tumorales épithéliales circulantes provenant d'un fluide corporel
EP2504698B1 (fr) Procédé permettant de prévoir la réponse d'une pathologie tumorale à une mesure thérapeutique
EP1786929B1 (fr) Procede pour le diagnostic d'un cancer de l'ovaire
Alati et al. An in vitro micronucleus assay for determining the radiosensitivity of hepatocytes
DE69113737T2 (de) Verfahren und vorrichtung zur ausführung des zytotoxizitätsassays auf tumorzellen.
WO2004003548A1 (fr) Procede permettant la determination de proprietes et/ou la classification de macrophages circulants et ensemble d'analyse servant a la mise en oeuvre dudit procede
DE60023474T2 (de) Methode zur selektiven trennung von blutzellen unter verwendung von lektin
EP2634249B1 (fr) Procédé de séparation d'assemblages de cellules malignes et d'assemblages de cellules de stroma dans un échantillon tissulaire de tumeur maligne ex vivo
Saxena et al. Aging and destruction of blood erythrocytes in mice
EP1922545A1 (fr) Dosage immunologique in vitro fonctionnel
DE60216045T2 (de) Krebsdiagnoseverfahren
EP3583421B1 (fr) Nouveau système in vitro permettant de prédire l'efficacité de combinaisons de médicaments dans des cellules tumorales ou autres cellules cibles
DE102016104212B4 (de) Verfahren zur geeigneten Therapie- und Erkennungsmethoden beim Lungenkrebs
AT412026B (de) Verfahren zur diagnose eines zystischen ovarialkarzinoms
EP0971232B1 (fr) Détermination luminométrique d'ATP
DE102020215567A1 (de) Rückhaltevorrichtung und Verfahren zur Separierung von Zellen
DE102010064525B3 (de) Isolierung und funktionale Identifizierung ganzer Zellen
Villani et al. 3D High Content Imaging of Optically-Cleared Microtissues for Screening Islet Cell Proliferation
Moser et al. G0–G1 transition of rat hepatocytes detected by changes in nuclear chromatin condensation after in vivo treatment with phenobarbital
DE4335057A1 (de) Verfahren und Testbesteck zum Nachweis zytotoxischer Mechanismen in vitro

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20120614

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20140922

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20170926

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

Free format text: NOT ENGLISH

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 979393

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180315

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: LANGUAGE OF EP DOCUMENT: GERMAN

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 502010014765

Country of ref document: DE

REG Reference to a national code

Ref country code: HR

Ref legal event code: TUEP

Ref document number: P20180906

Country of ref document: HR

REG Reference to a national code

Ref country code: RO

Ref legal event code: EPE

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20180614

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2504698

Country of ref document: PT

Date of ref document: 20180620

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20180614

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2673514

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180622

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20180314

REG Reference to a national code

Ref country code: HR

Ref legal event code: T1PR

Ref document number: P20180906

Country of ref document: HR

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E037770

Country of ref document: HU

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

REG Reference to a national code

Ref country code: SK

Ref legal event code: T3

Ref document number: E 27833

Country of ref document: SK

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180906

Country of ref document: HR

Payment date: 20181114

Year of fee payment: 9

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 502010014765

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20180401606

Country of ref document: GR

Effective date: 20190109

26N No opposition filed

Effective date: 20181217

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180314

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180906

Country of ref document: HR

Payment date: 20191119

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180314

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180714

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180906

Country of ref document: HR

Payment date: 20201113

Year of fee payment: 11

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180906

Country of ref document: HR

Payment date: 20211117

Year of fee payment: 12

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180906

Country of ref document: HR

Payment date: 20221116

Year of fee payment: 13

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230507

REG Reference to a national code

Ref country code: HR

Ref legal event code: ODRP

Ref document number: P20180906

Country of ref document: HR

Payment date: 20231114

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20231122

Year of fee payment: 14

Ref country code: LU

Payment date: 20231120

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SK

Payment date: 20231116

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20231120

Year of fee payment: 14

Ref country code: GB

Payment date: 20231123

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231215

Year of fee payment: 14

P02 Opt-out of the competence of the unified patent court (upc) changed

Effective date: 20231221

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: TR

Payment date: 20231116

Year of fee payment: 14

Ref country code: SI

Payment date: 20231114

Year of fee payment: 14

Ref country code: SE

Payment date: 20231123

Year of fee payment: 14

Ref country code: RO

Payment date: 20231117

Year of fee payment: 14

Ref country code: PT

Payment date: 20231110

Year of fee payment: 14

Ref country code: NO

Payment date: 20231121

Year of fee payment: 14

Ref country code: IT

Payment date: 20231130

Year of fee payment: 14

Ref country code: IE

Payment date: 20231117

Year of fee payment: 14

Ref country code: HU

Payment date: 20231121

Year of fee payment: 14

Ref country code: HR

Payment date: 20231114

Year of fee payment: 14

Ref country code: FR

Payment date: 20231123

Year of fee payment: 14

Ref country code: DK

Payment date: 20231122

Year of fee payment: 14

Ref country code: DE

Payment date: 20230913

Year of fee payment: 14

Ref country code: CZ

Payment date: 20231110

Year of fee payment: 14

Ref country code: CH

Payment date: 20231202

Year of fee payment: 14

Ref country code: BG

Payment date: 20231117

Year of fee payment: 14

Ref country code: AT

Payment date: 20231117

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PL

Payment date: 20231017

Year of fee payment: 14

Ref country code: BE

Payment date: 20231121

Year of fee payment: 14